ZURICH, Aug 26 (Reuters) - Swiss biotech firm Actelion said an important condition for its acquisition of privately-held Ceptaris was met with Ceptaris gaining U.S. approval for its Valchlor gel.
The companies are now completing further closing conditions before the acquisition is concluded, Actelion said in a statement on Monday.
The U.S. health regulator FDA has approved Ceptaris Therapeutics' topical drug for treatment of a rare form of non-Hodgkin's lymphoma, Actelion said.
The Allschwil-based company said in July it already paid Ceptaris $25 million and will pay another $225 million when the deal closes.
Reporting by Alice Baghdjian